NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VR
Post# of 26
(Total Views: 244)
Posted On: 12/29/2017 4:55:16 PM
NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Visits Clinical Trial Facility in San Juan, Puerto Rico
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico. Per the release, this will be the site where the company’s research arm, Cannevert Therapeutics Ltd. (“CTL”), will be conducting its first human study of CTL-X, a cannabis strain targeting the pain management market. Speaking about the FDI clinical trial facility in this morning’s update, Veritas CEO Lui Franciosi stated, “I was very impressed by their Phase I and Phase II-III clinical trial units. They were fully staffed and had a complete array of standard medical and laboratory equipment along with a functioning pharmacy… Although the island took a big hit by Hurricane Maria this September, most of San Juan’s major clinical centers such as the FDI suffered little or no damage… We are pleased to see that IMC is fully operational and they are still on track to supply Current Good Manufacturing Practice (“cGMP”) medical cannabis for Cannevert’s upcoming study at FDI.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico. Per the release, this will be the site where the company’s research arm, Cannevert Therapeutics Ltd. (“CTL”), will be conducting its first human study of CTL-X, a cannabis strain targeting the pain management market. Speaking about the FDI clinical trial facility in this morning’s update, Veritas CEO Lui Franciosi stated, “I was very impressed by their Phase I and Phase II-III clinical trial units. They were fully staffed and had a complete array of standard medical and laboratory equipment along with a functioning pharmacy… Although the island took a big hit by Hurricane Maria this September, most of San Juan’s major clinical centers such as the FDI suffered little or no damage… We are pleased to see that IMC is fully operational and they are still on track to supply Current Good Manufacturing Practice (“cGMP”) medical cannabis for Cannevert’s upcoming study at FDI.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Indigenous Bloom Hemp Corp (VRTHF) Stock Research Links
Scroll down for more posts ▼